This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Petri, M. Articles by Kim, M. Search for Related Content PubMed PubMed Citation Articles by Petri, M. Articles by Kim, M. Social Bookmarking                   What's this?

Classification and definition of major flares in SLE clinical trials

Division of Rheumatology, Johns Hopkins University School of Medicine, 1830 E Monument Street, Suite 7500, Baltimore, MD 21205, USA; Fax: (+1) 410 614 0498; mpetri{at}welchlink.welch,jhu.edu

Jill Buyon

Hospital for Joint Diseases, New York, USA

Mimi Kim

Department of Environmental Medicine, New York Medical Center, New York, USA

Multiple reliable and valid disease activities indices exist and have been used successfully in longitudinal studies. However, the definition of flare, using these intruments, has not been universally decided or accepted. Because flare is one of the three major patterns of lupus activity, it will remain an important outcome measure in both longitudinal and clinical trial studies.

Key Words: systemic lupus erythematosus • flare • disease activity • SLEDAI

Lupus, Vol. 8, No. 8, 685-691 (1999)
DOI: 10.1191/096120399680411281


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. AGGARWAL, C. T. WILKE, A. S. PICKARD, V. VATS, R. MIKOLAITIS, L. FOGG, J. A. BLOCK, and M. JOLLY Psychometric Properties of the EuroQol-5D and Short Form-6D in Patients with Systemic Lupus Erythematosus J Rheumatol, June 1, 2009; 36(6): 1209 - 1216. [Abstract] [Full Text] [PDF]

				C Nannini, C. Crowson, E. Matteson, and K. Moder Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study Lupus, April 1, 2009; 18(5): 394 - 399. [Abstract] [PDF]

				T. ANDERSEN, L. MUNTHE-FOG, P. GARRED, and S. JACOBSEN Serum Levels of Ficolin-3 (Hakata Antigen) in Patients with Systemic Lupus Erythematosus J Rheumatol, April 1, 2009; 36(4): 757 - 759. [Abstract] [Full Text] [PDF]

				C Gordon, G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I-M Gilboe, F Houssiau, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus Ann Rheum Dis, April 1, 2009; 68(4): 470 - 476. [Abstract] [Full Text] [PDF]

				A. D. ASKANASE, D. J. WALLACE, M. H. WEISMAN, C.-E TSENG, L. BERNSTEIN, H. M. BELMONT, E. SEIDMAN, M. ISHIMORI, P. M. IZMIRLY, and J. P. BUYON Use of Pharmacogenetics, Enzymatic Phenotyping, and Metabolite Monitoring to Guide Treatment with Azathioprine in Patients with Systemic Lupus Erythematosus J Rheumatol, January 1, 2009; 36(1): 89 - 95. [Abstract] [Full Text] [PDF]

				A Tulunay, S Yavuz, H Direskeneli, and E Eksioglu-Demiralp CD8+CD28-, suppressive T cells in systemic lupus erythematosus Lupus, July 1, 2008; 17(7): 630 - 637. [Abstract] [PDF]

				S-S. Lee, S. Singh, L. Magder, and M. Petri Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus Lupus, February 1, 2008; 17(2): 114 - 123. [Abstract] [PDF]

				A. Sinclair, G. Appel, M.A. Dooley, E. Ginzler, D. Isenberg, D. Jayne, D. Wofsy, and N. Solomons Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS) Lupus, December 1, 2007; 16(12): 972 - 980. [Abstract] [PDF]

				M. Petri, M. Y. Kim, K. C. Kalunian, J. Grossman, B. H. Hahn, L. R. Sammaritano, M. Lockshin, J. T. Merrill, H. M. Belmont, A. D. Askanase, et al. Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus N. Engl. J. Med., December 15, 2005; 353(24): 2550 - 2558. [Abstract] [Full Text] [PDF]

				J. P. Buyon, M. A. Petri, M. Y. Kim, K. C. Kalunian, J. Grossman, B. H. Hahn, J. T. Merrill, L. Sammaritano, M. Lockshin, G. S. Alarcon, et al. The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial Ann Intern Med, June 21, 2005; 142(12_Part_1): 953 - 962. [Abstract] [Full Text] [PDF]

				A. J. Gross, D. Hochberg, W. M. Rand, and D. A. Thorley-Lawson EBV and Systemic Lupus Erythematosus: A New Perspective J. Immunol., June 1, 2005; 174(11): 6599 - 6607. [Abstract] [Full Text] [PDF]

				J Schiffenbauer and L S Simon Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus, May 1, 2004; 13(5): 398 - 405. [Abstract] [PDF]

				V Strand Clinical trial design in systemic lupus erythematosus: lessons learned and future directions Lupus, May 1, 2004; 13(5): 406 - 411. [Abstract] [PDF]

				H I Brunner, O Y Jones, D J Lovell, A M Johnson, P Alexander, and M S Klein-Gitelman Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage Lupus, August 1, 2003; 12(8): 600 - 606. [Abstract] [PDF]

				J Jimenez-Alonso, J M Sabio, F Perez-Alvarez, I Reche, C Hidalgo, L Jaimez, and Grupo Lupus Virgen de las Nieves Hair dye treatment use and clinical course in patients with systemic lupus erythematosus and cutaneous lupus Lupus, July 1, 2002; 11(7): 430 - 434. [Abstract] [PDF]